US 12428395
Heterocyclic compounds as kinase inhibitor and uses thereof
granted A61PA61P35/00
Quick answer
US patent 12428395 (Heterocyclic compounds as kinase inhibitor and uses thereof) held by SPEROGENIX THERAPEUTICS LIMITED expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- SPEROGENIX THERAPEUTICS LIMITED
- Grant date
- Tue Sep 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61P, A61P35/00